CGEM Stock Price, Chart, Stats & News
Cullinan Therapeutics, Inc. (CGEM) does not currently pay a dividend.
CGEM chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.04% |
ROE | -46.19% |
D/E | 0.01x |
Interest coverage ratio | – |
CGEM valuation
P/E | – |
P/S | – |
P/B | 1.86x |
P/CF | -4.33x |
P/FCF | -5.60x |
P/OCF | -4.33x |
PEG | 2.55x |
EV multiple | -3.57x |
About
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
